AI assistant
CHIMERIC THERAPEUTICS LIMITED — Capital/Financing Update 2021
Jan 14, 2021
64648_rns_2021-01-14_84f04f40-18af-4cbb-bc4e-0b93b8eac90e.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Market Announcement
==> picture [33 x 50] intentionally omitted <==
15 January 2021
==> picture [451 x 5] intentionally omitted <==
Chimeric Therapeutics Limited (ASX: CHM) – Admission and Commencement of Official Quotation
Description
Chimeric Therapeutics Limited (‘CHM’) was admitted to the Official List of ASX Limited (‘ASX’) today, Friday, 15 January 2021.
Official quotation of CHM’s ordinary fully paid shares will commence at 11:00 AM AEDT on Monday, 18 January 2021.
CHM raised approximately $35 million pursuant to the offer under its prospectus dated 23 November 2020 (‘Prospectus’) by the issue of 175,000,000 shares at an issue price of $0.20 per share.
Quotation information
| Quoted Securities: | 196,500,000 fully paid ordinary shares |
|---|---|
| ASX Code: | CHM |
| Time: | 11:00 AM AEDT |
| Date: | Monday, 18 January 2021 |
| ASX Trade Abbreviation: | CHIMERIC |
| ISIN: | AU0000121576 |
| Home Branch: | Sydney |
| Registered Office: | Address: C/- The CFO Solution |
| Level 3, 62 Lygon Street, Carlton South VIC 3053 | |
| Phone: 03 9824 5254 | |
| Email: [email protected] | |
| Company Secretary: | Nathan Jong and Phillip Hains |
| Share Registry: | Boardroom Pty Limited |
| Address: Level 12, 225 George Street, Sydney NSW 2000 | |
| Phone (Investor Services): 1300 737 760 | |
| Email:[email protected] | |
| Balance Date: | 30 June |
| CHESS: | Participating. CHESS and Issuer Sponsored. |
| Place of Incorporation: | New South Wales |
| Dividend Policy: | See section 5.9 of the Prospectus |
| Activities: | Biotechnology company developing a cancer cell therapy drug |
| Lead Manager: | Bell Potter Securities Limited |
| Baker Young Limited |
Market Announcement 1/2 ASX Customer Service Centre 131 279 | asx.com.au
15 January 2021 ASX Limited
==> picture [33 x 50] intentionally omitted <==
| Underwriter: | NA |
|---|---|
| ASX Restricted Securities: | 115,226,336 fully paid ordinary shares classified by ASX as restricted |
| securities and to be held in escrow until 18 January 2023, being 24 months | |
| from the date of official quotation of securities. | |
| 4,957,897 unquoted options exercisable at $0.30 on or before 18 January | |
| 2024, classified by ASX as restricted securities and to be held in escrow | |
| until 18 January 2023, being 24 months from the date of official quotation | |
| of securities. | |
| 5,500,000 unquoted options exercisable at $0.20 on or before 18 January | |
| 2025, classified by ASX as restricted securities and to be held in escrow | |
| until 18 January 2023, being 24 months from the date of official quotation | |
| of securities. | |
| 18,800,065 fully paid ordinary shares classified by ASX as restricted | |
| securities and to be held in escrow until 1 September 2021, being 12 | |
| months from the date of issue. | |
| Other Securities Not Quoted: | 6,280,002 options exercisable at $0.20 expiring on or before 18 January |
| 2025 | |
| 6,280,002 options exercisable at $0.20 expiring on or before 18 January | |
| 2026 |
What do I need to do and by when?
Please refer to CHM’s Prospectus.
Need more information?
For further information, please call the Chimeric Information Line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) between 9:00am and 5:00pm AEDT.
Disclaimer
Please refer to the following disclaimer.
Issued by
Belinda Chiu
Senior Adviser, Listings Compliance (Sydney)
Market Announcement 2/2
15 January 2021